Police Seize Over 4000 e-Cigarette Pods in Drug Raid

Regulations by 2FIRSTS.ai
Jun.20.2024
Police Seize Over 4000 e-Cigarette Pods in Drug Raid
New Taipei City police seized over 4000 e-cigarette pods in a drug raid based on a tip, leading to an arrest.

According to a report from Focustaiwan on June 20th, the police in New Taipei City, Taiwan seized over 4,000 e-cigarette replacement pods in a drug raid last week.


According to a press release from the agency, this drug bust was carried out based on an anonymous tip, which reported that a resident in Sanchong District had stockpiled a large number of e-cigarette pods at home. At 5 pm on June 13, the police raided the residence of a 24-year-old man surnamed Dong and seized thousands of replacement pods in various flavors.


According to the police, the man purchased these pods online and sold them on social media platforms, which was his main source of income. In a raid, authorities seized a total of 4,189 pods, estimated to have a market value of 1 million New Taiwan Dollars (approximately $30,868 USD).


In the testing, it was found that these pods contained "Methoxy Ma Huang Tang", a synthetic stimulant classified as a Class III drug in Taiwan, China.


Currently, the man has been arrested and transferred to the New Taipei District Prosecutors Office in Taiwan for investigation on suspicion of violating Taiwan's Harm Prevention Act.


The "Tobacco Hazards Prevention Act" in Taiwan, China prohibits the production, sale, import, supply, and advertising of "imitation tobacco products," including electronic nicotine and non-nicotine delivery systems such as e-cigarettes, pods, and vape pens.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
Malaysia High Court Sets May 15 Ruling on NGOs’ Challenge to Vape Nicotine Poisons List Exemption
Malaysia High Court Sets May 15 Ruling on NGOs’ Challenge to Vape Nicotine Poisons List Exemption
Malaysia’s High Court has fixed May 15, 2026, to deliver its decision on a judicial review application by three NGOs challenging the government’s move to exempt vape liquids and gels from the Poisons List. The applicants argue the March 31, 2023 delisting effectively deregulated vape products and created a prolonged gap until Act 852 took effect in October 2024.
Jan.30 by 2FIRSTS.ai
Indonesia’s Vape Excise Revenue Rises 7.38% in 2025 to $170.4M Amid Broader Tobacco Excise Decline
Indonesia’s Vape Excise Revenue Rises 7.38% in 2025 to $170.4M Amid Broader Tobacco Excise Decline
Indonesia’s customs data show vape (REL) excise revenue reached Rp 2.84 trillion in 2025 (≈$170.4 million), up 7.38% year over year. The gain came even as overall tobacco excise revenue declined. Minimum retail price benchmarks (HJE) for vape products rose in 2025, while excise rates remained unchanged from 2024; open-system e-liquids accounted for the largest share of revenue.
Jan.27 by 2FIRSTS.ai
Make Your Brand Understood by the People Who Matter
Make Your Brand Understood by the People Who Matter
Feb.02
2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
2Firsts held its second U.S. PMTA compliance training in Shenzhen, providing a systematic overview of the U.S. regulatory framework for e-cigarettes and corporate compliance strategies. Nearly 20 industry professionals from manufacturing, e-liquid and supply-chain companies attended. Participants who passed the exam received compliance certification. Registration for the third training session will open soon, alongside customized corporate training programs.
Mar.09
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai